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doi:10.1016/j.jacl.2012.01.006BACKGROUND: Lecithin:cholesterol acyltransferase (LCAT) is responsible for cholesterol esterifi-
cation in plasma. Mutations of LCAT gene cause familial LCAT deficiency, a metabolic disorder char-
acterized by hypoalphalipoproteinemia. Apolipoprotein B (apoB) is the main protein component of
very-low-density lipoproteins and low-density lipoprotein (LDL). Mutations of APOB gene cause
familial hypobetalipoproteinemia, a codominant disorder characterized by low plasma levels of LDL
cholesterol and apoB.
OBJECTIVE: This was a genetic and biochemical analysis of an Italian kindred with hypobetalipo-
proteinemia whose proband presented with hypoalphalipoproteinemia and severe chronic kidney dis-
ease.
METHODS: Plasma lipids and apolipoproteins, cholesterol esterification, and high-density lipopro-
tein (HDL) subclass distribution were analyzed. LCAT and APOB genes were sequenced.
RESULTS: The proband had severe impairment of plasma cholesterol esterification and high preb-
HDL content. He was heterozygote for the novel LCAT P406L variant, as were two other family
members. The proband’s wife and children presented with familial hypobetalipoproteinemia and
were heterozygotes for the novel apoB H1401R variant. Cholesterol esterification rate of apoB
H1401R carriers was reduced, likely attributable to the low amount of circulating LDL. After renal
transplantation, proband’s lipid profile, HDL subclass distribution, and plasma cholesterol esterification
were almost at normal levels, suggesting a mild contribution of the LCAT P406L variant to his pre-
transplantation severe hypoalphalipoproteinemia and impairment of plasma cholesterol esterification.
CONCLUSION: LCAT P406L variant had a mild effect on lipid profile, HDL subclass distribution,
and plasma cholesterol esterification. ApoB H1401R variant was identified as possible cause of familial
hypobetalipoproteinemia and resulted in a reduction of cholesterol esterification rate.
 2012 National Lipid Association. All rights reserved.imi.it
for publication January 24, 2012.
National Lipid Association. All rights reserved.
Conca et al Novel missense variants in LCAT and APOB genes 245Lecithin:cholesterol acyltransferase (LCAT) is a 416-Figure 1 Pedigree of the family. The proband is indicated by an
arrow. Left or right filled symbols indicate heterozygous carriers
of LCAT (black) and apoB (gray) variants; white symbols indicate
noncarrier relatives (square, male; circle, female). Slashed sym-
bols indicate deceased individuals; N/A indicates family members
not available for analysis.amino acid protein responsible for the synthesis of choles-
teryl esters in human plasma; LCAT is also one of the key
enzymes involved in high-density lipoprotein (HDL)
metabolism.1 The LCAT gene, located on chromosome
16q22.1, spans 4.2 kb and comprises 6 exons and 5 introns2;
mutations in this gene cause LCAT deficiency, a rare meta-
bolic disorder with two syndromes: classic familial LCAT
deficiency (FLD; OMIM no. 245900), characterized by a
complete lack of enzyme activity, and fish-eye disease
(FED; OMIM no. 136120), characterized by a partially de-
fective enzyme, both inherited via an autosomal-recessive
patterns.3 Subjects with FLD and FED have hypoalphalipo-
proteinemia and impairment of cholesterol esterification in
plasma.3 Homozygous FLD cases reportedly present with
corneal opacity and anemia, and many of them unpredict-
ably develop renal disease. The FED cases have a milder
clinical phenotype. Heterozygous carriers have an interme-
diate lipid/lipoprotein phenotype, with a significant LCAT
gene dose-dependent effect on plasma cholesterol esterifi-
cation and lipid and apolipoprotein levels.3
Apolipoprotein B (apoB) is the major protein component
of very-low-density (VLDL) and low-density lipoproteins
(LDL) and plays a central role in human lipoprotein
metabolism.4 The human APOB gene is located on chromo-
some 2p24-p23; it consists of 29 exons and produces, via a
unique mRNA editing process, two forms of apoB: apoB-
48 (2152 amino acids) and apoB-100 (4563 amino acids).4
Mutations in the APOB gene cause familial hypobetalipo-
proteinemia (FHBL; OMIM no. 107730), an autosomal
codominant disorder characterized by very low plasma
levels of total cholesterol, LDL cholesterol, and apoB.5
Most mutations interfere with the translation of full-
length apoB mRNA and cause the production of truncated
apoBs of various size; only few nonsynonymous, nontrun-
cating mutations have been reported so far as cause of
FHBL.5–7 Homozygous FHBL is extremely rare and it is
associated with fatty liver, steatorrhea, intestinal fat malab-
sorption, and neurological abnormalities; FHBL heterozy-
gotes may be asymptomatic or present with fatty liver
disease and mild elevation of serum liver enzymes.5 In
the present study, an Italian kindred with two novel mis-
sense variants in the LCAT and APOB genes is described.Methods
The study was approved by the local institutional ethic
committee, and all subjects provided written informed
consent for participation in the study.Subjects
The proband (subject II.5, Fig. 1), a 53-year-old white
man from northern Italy, was referred to our lipid clinic
for severe hypoalphalipoproteinemia (HDL cholesterol be-
low the 5th percentile for the general population) during anepidemiological study on the dialytic population of an Ital-
ian Region in 2008. At 24 years of age, he had episodic
macroscopic hematuria and demonstrated persistent micro-
hematuria, proteinuria (1.5 g/L), and granulous cilindruria
with normal renal function. Because of severe malignant
hypertension and reduced renal function (creatinine clear-
ance 58 mL/min), 6 years later he underwent renal biopsy
that demonstrated chronic mesangial IgA glomerulonephri-
tis together with severe hypertensive microvascular damage
and no evidence of lipid deposits in the kidney.
Because of the following chronic renal insufficiency, he
started dialysis therapy at 35 years of age. In 1990 he
underwent a first renal transplantation from living donor
(mother), but because of chronic rejection, he returned to
hemodialysis in 2007. In 2009 he underwent a second,
cadaveric, renal transplantation that is actually well func-
tioning; he was given steroids, tacrolimus, and micofenolic
acid (creatinine 1.7 mg/dL; creatinine clearance 57 mL/
min). Blood samples were taken in 2008 (pretransplanta-
tion) and 10 months after the second transplantation (post-
transplantation). The proband’s pedigree spans three gen-
erations and includes 14 living subjects (Fig. 1). All sub-
jects had normal plasma creatinine and creatinine
clearance values.
Plasma lipids and apolipoproteins
After the patient fasted, his blood was collected into
tubes containing Na2-EDTA (final concentration 1 mg/mL);
plasma was prepared by low-speed centrifugation, and ali-
quots were immediately frozen at –80C. Plasma total and
unesterified cholesterol, high-density lipoprotein (HDL)
cholesterol, and triglycerides were determined with stan-
dard enzymatic techniques. LDL cholesterol was calculated
with the Friedewald’s formula. ApoA-I, apoA-II, and apoB
levels were determined by immunoturbidimetry. The pres-
ence of lipoprotein X was evaluated by lipoprotein electro-
phoresis on agarose gels. ApoE phenotyping was performed
by isoelectric focusing.8
Table 1 Lipid and apolipoprotein levels
I.2 I.4 II.1 II.3 II.5 II.6 II.7 II.8 II.9 III.1 III.2 III.3
Age, yr 89 75 68 63 54 48 47 42 39 18 14 12
Gender F F F F M F F F M F M M
LCAT genotype WT WT WT P406L P406L WT WT WT WT WT WT P406L
ApoB genotype WT WT WT WT WT WT H1401R WT WT H1401R H1401R H1401R
Total cholesterol, mg/dL 175 243 232 248 200 183 159 241 227 131 117 123
Triglycerides, mg/dL 76 94 91 81 254 54 58 102 85 72 44 41
Unesterified cholesterol,
mg/dL
52 56 60 66 64 42 44 53 50 40 34 33
Unesterified/total
cholesterol
0.29 0.23 0.26 0.27 0.32 0.23 0.28 0.22 0.22 0.31 0.29 0.27
LDL cholesterol, mg/dL 103 159 156 160 125 91 82 169 158 67 58 61
HDL cholesterol, mg/dL 57 65 58 72 24 81 65 52 52 50 50 54
Apolipoprotein A-I, mg/dL 120 153 131 165 73 175 129 131 124 103 91 109
Apolipoprotein A-II, mg/dL 23 31 33 33 21 25 25 28 25 22 26 31
Apolipoprotein B, mg/dL 77 124 112 117 88 69 58 132 117 50 40 45
246 Journal of Clinical Lipidology, Vol 6, No 3, June 2012Genetic analysis
Genomic DNA was isolated from lymphocytes of
peripheral blood samples using the salting out procedure.9
The six exons and the intronic flanking sequences of the
LCAT gene were amplified by polymerase chain reaction
(PCR) as previously described.10 PCR products were puri-
fied by solid-phase extraction (QIAquick PCR purification
Kit; QIAGEN, Hilden, Germany) and sequenced with the
Applied Biosystems Taq DyeDeoxy terminator cycle
sequencing kit (Applied Biosystems, Carlsbad, CA). Se-
quencing reactions were separated on the ABI PRISM
3730 sequencer (Applied Biosystems).
The entire APOB gene-coding region, including the 50-
flanking region and at least 50 base pairs of intronic
sequence at each intron–exon boundary, were amplified by
PCR, as described previously.11 Sequences were detected
on an Applied Biosystems 3100 DNA sequencer, and results
were analyzed with ABI PRISM SeqScape software
(Applied Biosystems).
All available family members and 100 healthy controls
were screened for the novel variants in LCAT and APOB
genes by denaturing high-performance liquid chromatogra-
phy or by sequencing the appropriate APOB gene regions,
respectively.Table 2 Cholesterol esterification process
I.2 I.4 II.1 II.3 II.5 II.6 II.
LCAT genotype WT WT WT P406L P406L WT WT
ApoB genotype WT WT WT WT WT WT H1
LCAT, mg/mL 5.60 5.44 5.97 5.53 2.78 4.49 5
CER, nmol/ml/h 38.2 47.3 42.1 24.1 8.3 29.4 21
LCAT activity,
nmol/mL/h
37.9 41.9 38.3 37.1 14.9 45.2 25
ApoB, apolipoprotein B; CER, cholesterol esterification rate; LCAT, lecithinIn silico analysis of missense variants
A computational analysis of novel missense variants of
LCAT and apoB was performed with the PolyPhen (http://
genetics.bwh.harvard.edu/pph/) and PANTHER (http://
www.pantherdb.org/) programs.12,13
Cholesterol esterification process
The esterification of cholesterol within endogenous lip-
oproteins (cholesterol esterification rate), or incorporated
into an exogenous standardized substrate (LCAT activity)
was determined as previously described.3 Plasma LCAT con-
centration was measured by an immunoenzymatic assay.14
HDL and LDL subclasses
The plasma concentration of HDL particles containing
only apoA-I (LpA-I) and of particles containing both
apoA-I and apoA-II (LpA-I:A-II) was determined by
electroimmunodiffusion in agarose gel (Sebia Italia, Fire-
nze, Italy).15 HDL subclass distribution for size was deter-
mined by nondenaturing polyacrylamide gradient gel
electrophoresis of the d,1.21 g/mL plasma total lipopro-
tein fraction; the HDL profile was divided into three size7 II.8 II.9 III.1 III.2 III.3
Reference
values
WT WT WT WT P406L –
401R WT WT H1401R H1401R H1401R –
.23 4.94 4.85 4.99 5.45 5.60 3.1–6.7
.1 39.9 34.3 23.0 19.8 19.3 30–60
.2 38.5 37.6 33.7 45.2 35.5 25–55
:cholesterol acyltransferase.
Table 3 HDL and LDL subclasses
I.2 I.4 II.1 II.3 II.5 II.6 II.7 II.8 II.9 III.1 III.2 III.3
Reference
values
LCAT genotype WT WT WT P406L P406L WT WT WT WT WT WT P406L –
ApoB genotype WT WT WT WT WT WT H1401R WT WT H1401R H1401R H1401R –
LpA-I, mg/dL 67 88 66 74 43 98 62 53 50 57 43 49 .42
LpA-I:A-II, mg/dL 53 65 65 91 30 77 67 78 74 46 48 60 .58
Small HDL, % 15.9 15.2 20.6 16.3 15.2 12.1 15.2 23.0 23.3 16.1 17.2 16.5 6.9–23.7
Medium HDL, % 11.3 19.5 17.3 14.2 18.1 22.2 14.9 23.0 21.6 11.4 12.2 17.1 13.5–30.3
Large HDL, % 72.8 65.3 62.1 69.4 66.7 65.7 69.9 54.0 55.1 72.5 70.6 66.4 50.5–75.3
Preb-HDL, % 13.1 11.8 10.8 12.9 20.9 14.6 11.4 13.8 11.9 12.2 10.4 10.5 10–14
LDL size, nm 27.3 27.5 26.4 27.4 27.3 27.5 27.6 27.5 27.5 26.7 27.4 27.2 .25.5
HDL, high-density lipoprotein; LCAT, lecithin:cholesterol acyltransferase.; LDL, low-density lipoprotein; LpA-I, particles containing only apoA-I; LpA-
I:A-II, particles containing both apoA-I and apoA-II.
Small HDL indicates HDL particle diameters ,8.2 nm; medium, particle diameters 8.2 , nm , 8.8; and large, particle diameter .8.8 nm.
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8.2–8.8 nm), and large HDL (diameter 8.8–12.7 nm).15
HDL subclasses were also analyzed by nondenaturing
two-dimensional (2D)-electrophoresis followed by immu-
nodetection against human apoA-I and serum content of
preb-HDL was expressed as percentage of total apoA-I.15
LDL particle size was analyzed by nondenaturing pol-
yacrylamide gradient gel electrophoresis with the Pharma-
cia Phast System (GE Healthcare BioSciences, Uppsala,
Sweden), as previously reported.8Results
Plasma lipids and apolipoproteins
Plasma levels of lipids and apolipoproteins are reported
in Table 1. At the first evaluation in 2008, the proband (II.5)
had very low levels of plasma HDL cholesterol and apoA-I
and high plasma triglycerides; the unesterified/total choles-
terol ratio was also higher than the normal reference value
(,0.30). Biochemical analyses were extended to all avail-
able family members. No reductions of HDL cholesterol
and apoA-I plasma levels were detected in proband’sFigure 2 Pre- and post-transplantation lipid and apolipoprotein levels.
during hemodialysis (pre-transplant) and 10 months after the second rerelatives; only the proband’s daughter (III.1) had borderline
high unesterified/total cholesterol ratio.
Interestingly, the lipid profile of the proband’s children
(III.1, III.2, and III.3) and wife (II.7) was suggestive of
FHBL, characterized by low plasma levels of LDL-
cholesterol and apoB, with a vertical transmission of the
lipid/apoB phenotype.7 Lipoprotein X was not detected in
the plasma of the proband and of other family members.
All subjects carried the E3/E3 phenotype.
DNA sequencing analysis
The hypoalphalipoproteinemia associated with the high
unesterified/total cholesterol ratio of the proband was sug-
gestive of a defect in the cholesterol esterification process;
thus, the analysis of LCAT gene was performed. The pro-
band (II.5) was indeed found to be heterozygous for a novel
point variant at c.1289 (C to T transition), which caused a
leucine for proline substitution at position 406, P406L. Pro-
band’s sister (II.3) and son (III.3) were also heterozygotes
for the P406L variant. A cohort of 100 healthy controls
was screened with denaturing high-performance liquid chro-
matography analysis to verify the frequency of the variant
and no subject carrying the P406L substitution was found.Proband’s plasma levels of HDL-C, apoA-I, and apoA-II measured
nal transplant (post-transplant) are shown.
Figure 3 Pre- and post-transplantation HDL subclass distribution. A, Plasma levels of HDL containing only apoA-I (LpA-I) and HDL
containing both apoA-I and apoA-II (LpA-I:A-II) measured during hemodialysis (pre-transplant) and 10 months after the second renal
transplant (post-transplant). B, Representative 2D-electrophoresis developed against apoA-I and percentage of preb-HDL by densitometry
evaluated on proband’s plasma samples collected during hemodialysis (pre-transplant) and 10 months after the second renal transplantation
(post-transplant).
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was extended to APOB gene. Subjects II.7, III.1, III.2, and
III.3 were indeed found to be heterozygous for a novel
point variant at c.4411 (A to G transition), which caused
an arginine for histidine substitution at position 1401
(H1401R). The H1401R variant was not detected in 100
healthy controls screened by direct sequencing of the can-
didate gene region. The amino acid residue at position
1401 is highly conserved among species.
In silico analysis of missense variants
The computational analyses performed with the Poly-
Phen and Panther programs suggest that the LCAT P406Lvariant should not affect LCAT function (PolyPhen predic-
tion: benign; Panther SubPSEC -1.4115, Pdeleterious 0.1696);
on the contrary, the apoB H1401R variant is expected to
have deleterious effect on apoB function (PolyPhen pre-
diction: probably damaging; Panther SubPSEC -4.7431,
Pdeleterious 0.8511).
Impact of variants on cholesterol esterification
process
The proband (II.5) had markedly low cholesterol ester-
ification rate, LCAT concentration, and activity (Table 2), a
very severe biochemical phenotype for a heterozygous car-
rier of LCAT variants.3 Family members carriers of the
Figure 4 Pre- and post-transplantation plasma cholesterol esterification. Unesterified/total cholesterol ratio (UC/TC), plasma level of
LCAT, cholesterol esterification rate (CER), and LCAT activity measured during hemodialysis (pre-transplant), and 10 months after the
second renal transplant (post-transplant).
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showed reduced levels of plasma cholesterol esterification
rate (Table 2). This impairment of cholesterol esterification
was caused neither by reduced plasma levels of LCAT nor
to a defective LCAT enzyme, since LCAT activity, which is
measured on exogenous lipoproteins, was normal (Table 2).
Impact of variants on HDL and LDL subclasses
The proband displayed a low plasma level of LpA-I:A-II
and an increased percentage of preb-HDL. On average,
neither the LCAT P406L nor the apoB H1401R mutant
significantly affected HDL subclass distribution for protein
composition, size and shape (Table 3). Indeed, LpA-I and
LpA-I:A-II levels were within the normal range; HDL
distribution according to particle size and percentage of dis-
coidal preb-migrating HDL were also comparable between
carriers of the mutants and non carrier relatives. No altera-
tion of LDL size was detected (Table 3).
Pre- and post-transplant values
The proband’s lipid profile was reanalyzed 10 months
after the second renal transplantation. Compared with
values before the patient underwent transplantation, total
and LDL cholesterol slightly increased to 227 and 144 mg/
dL, respectively; triglycerides markedly decreased from
254 to 164 mg/dL. Notably, HDL cholesterol and apoA-I
levels increased to 50 and 112 mg/dL, respectively (Fig. 2).
HDL subclass distribution was also normalized: LpA-I:A-II
increased from 30 to 70 mg/dL, whereas preb-HDL de-
creased to 12.6% (Fig. 3). Plasma cholesterol esterification
was also improved after transplantation; indeed, unesteri-
fied/total cholesterol ratio, LCAT concentration, and activ-
ity were normalized, whereas the cholesterol esterification
rate increased but was still lower than reference values
(19.8 nmol/mL/h; Fig. 4).Discussion
In the present work two novel missense variants in the
LCAT and APOB genes are described. In a three-generationItalian kindred, three heterozygous carriers of the novel
P406L variant of LCAT were found. This variant is local-
ized within the proline-rich C-terminal portion on LCAT
(residues 399–416); previous data showed that the complete
deletion of this portion did not impair LCAT protein secre-
tion, stability, and activity.16,17 In silico prediction of the
impact of leucine for proline at position 406 of LCAT se-
quence indicated that this substitution between nonpolar
amino acids should not affect LCAT expression and func-
tion. This prediction is strengthened by the biochemical
analyses performed on LCAT P406L carriers. Subjects
II.3 and III.3 did not display hypoalphalipoproteinemia
and impaired cholesterol esterification in plasma except
for a modest reduction of cholesterol esterification rate;
this finding is in contrast with the average profile of Italian
heterozygous carriers of LCAT mutations, which have
unesterified/total cholesterol ratios greater than 0.30 and
reduced LCAT activity.3
Further support to the mild effect of the LCAT P406L
variant comes from the almost complete normalization of
proband’s lipid profile 10 months after the second renal
transplantation. Indeed, when analyzed in 2008 while being
under hemodialysis, the proband displayed a severe reduc-
tion of plasma HDL cholesterol, LCAT concentration and
activity, and cholesterol esterification rate that was sugges-
tive of a very severe biochemical phenotype of LCAT
deficiency; however, after renal transplantation, only cho-
lesterol esterification rate was still below the normal range
(as it was for carriers II.3 and III.3). Thus, the LCAT
deficiency observed during hemodialysis was likely the
result of the additive effects of the LCAT genotype and of
the severe impairment of renal function.18 To further sup-
port this issue, renal biopsy showed chronic mesangial
IgA glomerulonephritis and no evidence of lipid deposits
in the kidney, a picture clearly different from the typical
form of renal damage observed in subjects with genetic
LCAT deficiency, that is focal glomerulosclerosis with vac-
uolization of glomerular basement membrane due to lipid
deposition.10
According to the mild effect of the P406L variant on
cholesterol esterification in plasma, HDL subclass distri-
bution was not altered in the carriers; in particular, the
percentage of preb-HDL particles was not increased, as
250 Journal of Clinical Lipidology, Vol 6, No 3, June 2012previously shown in Italian heterozygous carriers of LCAT
mutations.3 In addition, proband’s preb-HDL percentage,
that was elevated under hemodialysis, was markedly re-
duced concomitantly with the normalization of cholesterol
esterification achieved after renal transplantation.
Four family members presented with hypobetalipopro-
teinemia and were found to be carriers of a novel missense
variant of apolipoprotein B. Mutations in the APOB gene
causing FHBL are mainly frameshift or nonsense mutations
leading to truncated apoB forms, whereas missense muta-
tions are very rare.5 Here we found that subject II.7 and
her three children (III.1, III.2, and III.3) are heterozygous
carriers of a missense variant causing the substitution of
the histidine at position 1401 with the other basic amino
acid arginine. According to Segrest et al.19 this substitution
is located within the amphipatic b1 domain of apoB, which
generally is considered the major lipid-associating motif of
the protein and involved in the initiation of triglyceride as-
sembly in nascent apoB; on the contrary, the other missense
mutations of apoB described to date are located in the N-
terminal ba1 domain, likely involved in apoB intracellular
trafficking and secretion.7
The in silico classification of the apoB H1401R variant
as probably damaging associated with the vertical trans-
mission of moderate hypobetalipoproteinemia in the kin-
dred support apoB H1401R as possible causative of
FHBL.5 However, in vitro expression of this novel apoB
variant is needed to establish its biological effects. Carriers
of the apoB H1401R displayed moderate reduction of cho-
lesterol esterification rate; this reduction was not attribut-
able to a reduced LCAT expression or defective enzyme
activity, and it is likely consequent to the low amount of cir-
culating LDL, which together with HDL, acts as LCAT
substrates. Interestingly, subject III.3, who is a compound
heterozygote for both the LCAT P406L and apoB
H1401R variants, displayed a lipid profile, HDL subclass
distribution, and plasma cholesterol esterification similar
to that of his siblings III.1 and III.2, carrying only apoB
H1401R, further supporting the mild effect of the LCAT
P406L variant on carriers’ biochemical phenotype.Conclusion
The proband’s severe alteration of lipid profile, HDL
subclass distribution and cholesterol esterification in
plasma was the result of the LCAT P406L variant and of
the concomitant chronic renal insufficiency. The novel
apoB H1401R variant was found as possible cause of
FHBL observed in the kindred and associated with a
reduced cholesterol esterification rate.Financial disclosure
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